MCM
MRTX

McKinley Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

McKinley Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,665
Closed -$1.72M – 187
2021
Q2 		$1.72M Hold
10,665
– – 0.12% 129
2021
Q1 		$1.83M Hold
10,665
– – 0.14% 125
2020
Q4 		$2.34M Buy
+10,665
New +$2.31M 0.17% 116

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

McKinley Capital Management's MRTX Position: Q3 2021 in Review

McKinley Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 10,665 shares — an estimated $1.72M sold.

McKinley Capital Management first reported a position in MRTX in Q4 2020 and held it in 3 quarters. The position peaked at $2.34M in Q4 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

  • McKinley Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • McKinley Capital Management sold 10,665 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.72M.
  • McKinley Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • McKinley Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.34M in Q4 2020.
  • 238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on McKinley Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.